MEEX Speaker
Caroline A. Lee is a graduate from the department of Pharmaceutics, University of Washington. Following graduate school, she went to Glaxo as an industrial postdoctoral fellow. As a post-doc, Caroline worked on the co-expression of human cytochrome P450, P450 reductase and cytochrome b5 to produce functional enzyme utilizing the baculovirus/insect cell system. In 1996, she joined Agouron Pharmaceuticals, Inc. as a Research Scientist in the DMPK group. She worked on Viracept, Agouron’s only marketed medicine for HIV (HIV Protease Inhibitor). Agouron was acquired by Warner Lambert and then by Pfizer. With Pfizer, Caroline established a high throughput ADME screening group, providing permeability and P-gp transport information, metabolic stability and CYP mediated drug interaction support to La Jolla’s drug discovery programs. Due to re-organization and centralization of high throughput ADME screening, her group then provided mechanistic enzymology and transporter support to address difficult issues in drug discovery and fulfilling IND or NDA requirements to support filings. In the past several years, she has been involved in various transporter initiatives including contributing author to the PhRMA/DIA Transporter White Paper and leading a Pharmaceutical industry driven project to evaluate the variability in P-gp IC50 and refining appropriate universal in vitro cutoff values to better predict digoxin related DDIs. She is currently working as a consultant in the areas of DM/PK & Transporters.